Overview of the Drug and Generics: What Is Cialis Prescribed For and How Is It Different from Tadalafil

Cialis > generic cialis 5 mg


hydralazinetadalafil increases effects of hydralazine by pharmacodynamic synergism. tadalafil increases effects of hydralazine by pharmacodynamic synergism.

  • It is important to understand that results vary from person to person.
  • Factors like overall health, severity of condition, and adherence matter.
  • Patience is required; it may take weeks to see full benefits for BPH.
  • Keep a log of effects and side effects to discuss with your doctor.

hydrochlorothiazidetadalafil increases effects of hydrochlorothiazide by pharmacodynamic synergism.

Side Effects

fluvoxamine will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fosaprepitantfosaprepitant will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fosaprepitant will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fosinopriltadalafil increases effects of fosinopril by pharmacodynamic synergism. tadalafil increases effects of fosinopril by pharmacodynamic synergism.

What should I tell my healthcare provider before using tadalafil?

fosphenytoinfosphenytoin will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fosphenytoin will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. furosemidetadalafil increases effects of furosemide by pharmacodynamic synergism. tadalafil increases cialis canadian meds effects of furosemide by pharmacodynamic synergism. grapefruitgrapefruit will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tadalafil increases effects of hydrochlorothiazide by pharmacodynamic synergism. imatinibimatinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Product Dosage Quantity + Bonus Price
Cialis Generic10mg10 Pills31.41€ 29.91€
Cialis Original20mg12 Pills78.32€ 74.59€
Cialis Generic40mg60 + 6 Pills130.98€ 124.74€
Cialis Generic40mg270 + 10 Pills382.19€ 363.99€
Cialis Generic10mg120 + 6 Pills178.49€ 169.99€
Cialis Generic2.5mg10 Pills28.51€ 27.15€
Cialis Soft Tabs20mg180 + 8 Pills353.17€ 336.35€
Cialis Super Active20mg180 + 20 Pills521.59€ 496.75€
Cialis Black80mg120 + 8 Pills264.77€ 252.16€
Cialis Generic20mg120 + 8 Pills188.15€ 179.19€
Cialis Soft Tabs20mg60 + 4 Pills159.37€ 151.78€

imatinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. indapamidetadalafil increases effects of indapamide by pharmacodynamic synergism.

Which Makes You Harder?

grapefruit will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. griseofulvingriseofulvin will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. griseofulvin will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. guanfacinetadalafil increases effects of guanfacine by pharmacodynamic synergism. tadalafil increases effects of guanfacine by pharmacodynamic synergism. tadalafil increases effects of indapamide by pharmacodynamic synergism. irbesartantadalafil increases effects of irbesartan by pharmacodynamic synergism. tadalafil increases effects of irbesartan by pharmacodynamic synergism. isoniazidisoniazid will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. isoniazid will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. isradipinetadalafil increases effects of isradipine by pharmacodynamic synergism. tadalafil increases effects of isradipine by pharmacodynamic synergism. istradefyllineistradefylline will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

  • The medication can be taken during the day or at night.
  • Taking it at night may help mitigate side effects like headache.
  • Consistency in timing helps maintain a steady drug level in the blood.
  • Choose a time that is easy to remember for daily adherence.

Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates. istradefylline will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. labetaloltadalafil increases effects of labetalol by pharmacodynamic synergism. tadalafil increases effects of labetalol by pharmacodynamic synergism.

Comparing Which Lasts Longer

esmololtadalafil increases effects of esmolol by pharmacodynamic synergism. tadalafil increases effects of esmolol by pharmacodynamic synergism. ethacrynic acidtadalafil increases effects of ethacrynic acid by pharmacodynamic synergism. tadalafil increases effects of ethacrynic acid by pharmacodynamic synergism. Combination may increase risk of orthostatic hypotension, tachycardia, dizziness and headache.

Does tadalafil interact with other medicines (drug interactions)?

etravirineetravirine will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. etravirine will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fedratinibfedratinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Adjust dose of drugs that are CYP3A4 substrates as necessary. fedratinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Drug forms and strengths: 2.5 mg, 5 mg, 10 mg, 20 mg

felodipinetadalafil increases effects of felodipine by pharmacodynamic synergism. tadalafil increases effects of felodipine by pharmacodynamic synergism. fluconazolefluconazole will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fluconazole will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fluvoxaminefluvoxamine will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lapatiniblapatinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Are All Tadalafil Prescriptions the Same?

efavirenzefavirenz will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. efavirenz will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. elagolixelagolix decreases levels of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Consider increasing CYP3A substrate dose if needed. elagolix decreases levels of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Dosage for ED and BPH

Adjust tadalafil dose for PAH; if on Stribild, start tadalafil 20 mg/day; avoid tadalafil when starting Stribild; for ED, a single dose of tadalafil not exceeding 10 mg in 72 hr. enalapriltadalafil increases effects of enalapril by pharmacodynamic synergism. tadalafil increases effects of enalapril by pharmacodynamic synergism. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents.

Dosage forms

eplerenonetadalafil increases effects of eplerenone by pharmacodynamic synergism. tadalafil increases effects of eplerenone by pharmacodynamic synergism. eprosartantadalafil increases effects of eprosartan by pharmacodynamic synergism. tadalafil increases effects of eprosartan by pharmacodynamic synergism. eslicarbazepine acetate will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lapatinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. letermovirletermovir increases levels of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. letermovir increases levels of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lisinopriltadalafil increases effects of lisinopril by pharmacodynamic synergism. tadalafil increases effects of lisinopril by pharmacodynamic synergism. losartantadalafil increases effects of losartan by pharmacodynamic synergism. tadalafil increases effects of losartan by pharmacodynamic synergism. lumefantrinelumefantrine will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lumefantrine will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. marijuanamarijuana will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. marijuana will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

  • Generic Cialis offers a cost-effective alternative to brand-name Cialis.
  • It may be used to treat benign prostatic hyperplasia (BPH).
  • Taking it on an empty stomach can enhance absorption.
  • It usually starts working within 30 to 60 minutes.
  • Consult your doctor before starting treatment.

mavorixaformavorixafor will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor for adverse effects of sensitive CYP3A4 substrates if coadministered with mavorixafor (a weak CYP3A4 inhibitor). mavorixafor will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Parameter Description Typical Value Notes
Absorption Time to reach peak plasma concentration 2 hours Varies by individual
Half-life Time for plasma concentration to reduce by half 17.5 hours Provides extended window
Bioavailability Percentage of dose reaching systemic circulation 40% Oral administration
Metabolism Liver via CYP3A4 enzymes Primarily CYP3A4

metolazonetadalafil increases effects of metolazone by pharmacodynamic synergism. tadalafil increases effects of metolazone by pharmacodynamic synergism.

Understanding Tadalafil

dasatinibdasatinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. dasatinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. deferasiroxdeferasirox will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. deferasirox will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. dexamethasonedexamethasone will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

How long does tadalafil last?

dexamethasone will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. diltiazemdiltiazem will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. diltiazem will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tadalafil increases effects of doxazosin by pharmacodynamic synergism. dronedaronedronedarone will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Comparison with actions of other PDE5 inhibitors

dronedarone will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. duvelisibduvelisib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration with duvelisib increases AUC of a sensitive CYP3A4 substrate which may increase the risk of toxicities of these drugs. Consider reducing the dose of the sensitive CYP3A4 substrate and monitor for signs of toxicities of the coadministered sensitive CYP3A substrate. duvelisib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. metoprololtadalafil increases effects of metoprolol by pharmacodynamic synergism.

  • It is not approved for use in women or children.
  • Safety and efficacy have not been established for female patients.
  • It is strictly for adult male use under medical supervision.
  • There is no indication for pediatric use of this medication.

Scroll to top

Dr. med. Fabienne Gretener

Werdegang

Januar 2024 bis heute
Oberärztin SenoMed AG
Schwerpunktsweiterbildung gynäkologische Senology

März 2023 – Dezember 2023
Oberärztin, SenoMed AG Bern 20%

Januar 2023 – November 2023
Assistenzärztin Psychiatrie, Klinik Meissenberg Zug

Januar 2021 – November 2022
Assistenzärztin Gynecology und Geburtshilfe, Bürgerspital Solothurn

November 2019 – Oktober 2020
Assistenzärztin Gynecology und Geburtshilfe, Kantonsspital Aarau

Januar 2017 – Juli 2019
Assistenzärztin Gynecology und Geburtshilfe, Kantonsspital Olten

Paul Laszlo Bernhard

Werdegang

Jan 2024 bis heute
Facharzt SenoMed AG – Brustzentrum Bern Biel

Aug 2019 – Dez 2023
Oberarzt Frauenklinik und Brustzentrum Bürgerspital, Solothurn, Schwerpunktweiterbildung operative Gynecology und Geburtshilfe sowie Senology

Mai 2019 Facharzttitel Gynecology & Geburtshilfe

Apr 2016 – Jul 2019
Arzt in Weiterbildung, Inselspital Bern, Universitätsklinik für Frauenheilkunde

Dez 2014 – Apr 2016
Arzt in Weiterbildung, Kantonsspital Baden

Sep 2012 – Sep 2014
Arzt in Weiterbildung, Universitätsklinikum Carl Gustav Carus, Dresden

Feb 2012 – Sep 2012
Arzt in Weiterbildung, Universitätsfrauenklinik Leipzig

Nov 2011 Approbation zum Arzt

2005 – 2011
Studium der Humanmedizin an der Charité, Universitätsmedizin Berlin

Dr. med. Patrizia Sager

Werdegang

Okt 2023 bis heute
Leiterin Weiterbildungsstätte gynäkologische Senology

Feb 2018 – bis heute
Leiterin Brustzentrum Bern Biel
Practiceinhaberin SenoMed AG

Nov 2017 – bis heute
Belegärztin Salem-Spital Bern

Jan 2013 – Okt 2017
Leitung Senology Brustzentrum Frauenklinik Universitätsspital Insel, Bern

Jan 2012 – Dez 2012
Oberärztin Gynecology / Geburtshilfe, Frauenklinik Universitätsspital Insel, Bern

Nov 2010 – Dez 2011
Leitende Ärztin Gynecology und Geburtshilfe, Frauenklinik Rheinfelden (DE)

Nov 2009 – Okt 2010
Oberärztin Gynecology und Geburtshilfe, Kantonsspital Liestal

Jan 2009 – Okt 2009
Oberärztin i.V. Gynecology und Geburtshilfe, Regionalspital Interlaken

Jun 2008 – Dez 2008
Assistenzärztin Gynecology und Geburtshilfe, Regionalspital Interlaken

Aug 2007 – Mai 2008
Assistenzärztin Gynecology und Geburtshilfe, Universitätsspital Zürich

Feb 2007 – Jun 2007
Oberärztin Gynecology und Geburtshilfe, Universitätsspital Groote Schuur, Kapstadt, Südafrika

Jan 2004 – Dez 2006
Assistenzärztin Gynecology und Geburtshilfe, Regionalspital Thun

Jan 2003 – Dez 2003
Assistenzärztin Chirurgie und Orthopädie, Regionalspital Thun

Schulen, Studium & Diplome

2023
Schwerpunkt gynäkologische Senology

2014
Diplom Senology SGGG

2013
Diplom Senology: European Academy of Senology

2010
FMH Gynecology und Geburtshilfe inkl. Schwerpunkt operative Gynecology

2003
Promotion

2002
Staatsexamen in Humanmedizin

1996 – 2002
Humanmedizinstudium Universitätsspital Basel

Mitglied- und Partnerschaften

  • Schweizerische Gesellschaft für Gynecology und Geburtshilfe SGGG
  • Schweizerische Gesellschaft für Senology SGS
  • Mitglieder Arbeitsgemeinschaft Gynäkologische Onkologie AGO, Schweiz
  • European Academy of Senology EAoS
  • SAKK Project-Group breast cancer
  • Schweizerische Gesellschaft für Ultraschall in der Medizin SGUM
  • Verbindung der Schweizer Ärzte und Ärztinnen FMH
  • Society of women in senology SWIS
  • Vorstandsmitglied Ärztenetzwerk Bern